Pharmaceuticals

Sage and Biogen halt Phase 2 trial of new drug after failure to show significant improvement in treating essential tremor

bexib
By bexib 0 Min Read

Going forward, Sage Therapeutics and Biogen plan to discontinue further clinical development of SAGE-324 for essential tremor.

You Might Also Like

APL and CurifyLabs Partner to Support Patients with 3D Printed Medical Technology

Phase 2 PREDICT-ILD Imaging Study in Interstitial Lung Disease Begins

New ways to determine drug value with health equity in mind

Melissa Krebs Shares Gersana’s Vision for Innovative Wound Care Solutions

Zongertinib demonstrates high objective response rates in previously treated advanced non-small cell lung cancer

Share This Article
Previous Article Measuring inequality from multiple angles
Next Article Delta Air Lines expects flight disruptions to ease and operations to return to normal by Thursday Reuters – Investorempires.com
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

XTransfer and OCBC partner to provide enhanced financial services for small and medium-sized businesses
Fintech
Cocktail trends for 2025 by Three Cents
Hospitality & Tourism
OCBC awards S$7.5 million in financial aid to junior employees in their second year
Fintech
Large-scale inference models accelerate content marketing
Retail & E-commerce